PMID- 20659761
OWN - NLM
STAT- MEDLINE
DCOM- 20101228
LR  - 20151119
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 126
IP  - 3
DP  - 2010 Sep
TI  - In vitro comparison of dabigatran, unfractionated heparin, and 
      low-molecular-weight heparin in preventing thrombus formation on mechanical heart 
      valves.
PG  - e196-200
LID - 10.1016/j.thromres.2010.06.011 [doi]
AB  - INTRODUCTION: Lifelong oral anticoagulation (OAC) therapy is required for the 
      prevention of thromboembolic events after implantation of an artificial heart 
      valve. Thromboembolism and anticoagulant-related bleedings account for 
      approximately 75% of all complications experienced by heart valve recipients 
      (2-9% of patients per year). The present study investigated the efficacy of 
      dabigatran, a new direct thrombin inhibitor for oral use, as compared to 
      unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) in 
      preventing thrombus formation on mechanical heart valves in vitro. MATERIAL AND 
      METHODS: Blood (230 ml) from healthy young male volunteers was anticoagulated 
      either by dabigatran (1 micromol/l), UFH (150 IU), or LMWH (100 IU). Mechanical 
      heart valve prostheses were placed in an in vitro thrombosis tester and exposed 
      to the anticoagulated blood samples under continuous circulation at a rate of 75 
      beats per minute. RESULTS: In whole blood with no anticoagulant, the apparatus 
      completely clotted in 15-20 minutes. When blood was treated with dabigatran, the 
      mean thrombus weight was 164+/-55 mg, in the UFH group 159+/-69 mg, and in the 
      LMWH group 182+/-82 mg (p-value: 0.704). Electron microscopy showed no 
      significant difference in thrombus formation in any group. CONCLUSIONS: 
      Dabigatran was as effective as UFH and LMWH in preventing thrombus formation on 
      mechanical heart valves in our in vitro investigation. Thus, we hypothesize that 
      dabigatran etexilate might potentially be a useful and competitive orally 
      administered alternative to UFH and LMWH for recipients of alloplastic heart 
      valve prostheses.
CI  - Copyright (c) 2010 Elsevier Ltd. All rights reserved.
FAU - Maegdefessel, Lars
AU  - Maegdefessel L
AD  - Department of Medicine III at the University Hospital Haale (Saale), 
      Martin-Luther-University Halle-Wittenberg, Germany. maegdefessel@stanford.edu
FAU - Linde, Torsten
AU  - Linde T
FAU - Krapiec, Franziska
AU  - Krapiec F
FAU - Hamilton, Kathrin
AU  - Hamilton K
FAU - Steinseifer, Ulrich
AU  - Steinseifer U
FAU - van Ryn, Joanne
AU  - van Ryn J
FAU - Raaz, Uwe
AU  - Raaz U
FAU - Buerke, Michael
AU  - Buerke M
FAU - Werdan, Karl
AU  - Werdan K
FAU - Schlitt, Axel
AU  - Schlitt A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100724
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
RN  - 0 (Benzimidazoles)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Pyridines)
RN  - 9005-49-6 (Heparin)
RN  - I0VM4M70GC (Dabigatran)
SB  - IM
MH  - Administration, Oral
MH  - Anticoagulants/administration & dosage/*pharmacology
MH  - Benzimidazoles/administration & dosage/*pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Dabigatran
MH  - Fibrinolytic Agents/administration & dosage/*pharmacology
MH  - Heart Valve Prosthesis/*adverse effects
MH  - Heparin/administration & dosage/*pharmacology
MH  - Heparin, Low-Molecular-Weight/administration & dosage/*pharmacology
MH  - Humans
MH  - Male
MH  - Prosthesis Design
MH  - Pyridines/administration & dosage/*pharmacology
MH  - Thrombosis/blood/etiology/*prevention & control
MH  - Time Factors
EDAT- 2010/07/28 06:00
MHDA- 2010/12/29 06:00
CRDT- 2010/07/28 06:00
PHST- 2010/03/08 00:00 [received]
PHST- 2010/06/15 00:00 [revised]
PHST- 2010/06/16 00:00 [accepted]
PHST- 2010/07/28 06:00 [entrez]
PHST- 2010/07/28 06:00 [pubmed]
PHST- 2010/12/29 06:00 [medline]
AID - S0049-3848(10)00350-6 [pii]
AID - 10.1016/j.thromres.2010.06.011 [doi]
PST - ppublish
SO  - Thromb Res. 2010 Sep;126(3):e196-200. doi: 10.1016/j.thromres.2010.06.011. Epub 
      2010 Jul 24.